申请人:Shire Human Genetic Therapies, Inc.
公开号:US10760112B2
公开(公告)日:2020-09-01
The present invention provides, among other things, methods and compositions for determining enzyme kinetic parameters (e.g., Vmax, Km, and specific activity, etc.) indicative of clinically relevant properties of glucocerebrosidase using a physiologically relevant substrate, in particular, a substrate that is representative of substrates that typically accumulate in patients suffering from Gaucher disease such as glucosylceramide. Thus, the present invention is particularly useful to measure a kinetic parameter relating to the activity of glucocerebrosidase in a drug substance, drug product, and stability sample for enzyme replacement therapy.
本发明除其他外,提供了使用生理相关底物,特别是使用代表通常在戈谢病患者体内蓄积的底物(如葡萄糖甘油酰胺)来确定指示葡萄糖脑苷脂酶临床相关特性的酶动力学参数(如Vmax、Km和比活性等)的方法和组合物。因此,本发明特别适用于测量酶替代疗法的药物物质、药物产品和稳定性样品中与葡萄糖脑苷脂酶活性有关的动力学参数。